Triptorelin

Label

ClassGnRH agonist

Typical routes in papersDepot IM/SC on label

Half-life contextFormulation-dependent (1–6 month depots)

EvidenceApproved oncology / gyn / precocious-puberty uses

What it is

Triptorelin is a GnRH agonist given as a depot so the pituitary first surges, then shuts down LH/FSH. That castrate-range suppression is the medical point.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

On-label: prostate cancer, some gynecologic estrogen-suppression jobs, precocious puberty.
Forum “reset the axis with one tiny shot” stories use microdoses that are not the cancer depot. That is still hormone shutdown territory.
Opposite idea from pulsatile gonadorelin.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Continuous GnRH-receptor stimulation causes receptor down-regulation and hypogonadotropic hypogonadism after an initial flare.

Possible side effects / caveats

Flare, hot flashes, bone density loss, mood, and the full hypogonadal picture.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label depots	3.75–22.5 mg class	Monthly to 6-month IM	Oncology/gyn products
Anecdote microdoses	Do not copy	Not a labeled fertility hack	See gonadorelin instead for pulse logic

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.